Tolvaptan-induced isolated elevation of bilirubin in a patient with Gilbert syndrome.

Matthew Nguyen, Beshoy T Yanny, Tai Ld Truong, Hongyu Zhao, Ramy Hanna

Open access · goldAbstract readCase Reports

In one paragraph

Article in SAGE open medical case reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

0.3field-weighted citation impact, top 31% of its field

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

Novel OFD1 Mutation Results in Unusually Early-Onset Polycystic Kidney Disease.Case reports in nephrology and dialysis
Article

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Matthew NguyenDivision of Nephrology, Hypertension & Kidney Transplantation, Department of Medicine, University of California, Irvine Medical Center, Irvine, CA, USA.ORCID https://orcid.org/0000-0002-6517-041X

Beshoy T YannyVatche & Tamar Manoukian Division of Digestive Diseases, Department of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.

Tai Ld TruongDivision of Nephrology, Hypertension & Kidney Transplantation, Department of Medicine, University of California, Irvine Medical Center, Irvine, CA, USA.

Hongyu ZhaoDivision of Nephrology, Hypertension & Kidney Transplantation, Department of Medicine, University of California, Irvine Medical Center, Irvine, CA, USA.

Ramy HannaDivision of Nephrology, Hypertension & Kidney Transplantation, Department of Medicine, University of California, Irvine Medical Center, Irvine, CA, USA.

University of California, Irvine Medical Center · USUniversity of California, Los Angeles · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tolvaptan is the current standard of treatment for autosomal dominant polycystic kidney disease. It operates by acting on V2 receptors and blocks vasopressin interactions, causing a reduction in the rate of renal cyst growth and preserving kidney function. The current known risks of tolvaptan involve a serious liver injury characterized by an elevation in total bilirubin and alanine transaminase and aspartate transaminase levels. In this report, we document a unique liver injury characterized by an elevated bilirubin with normal alanine transaminase and aspartate transaminase levels in a patient who is homozygous for the UGT1A1 consistent with Gilbert syndrome.

Indexed as

autosomal dominant polycystic kidney diseaseGilbert’s syndromeTolvaptan

Identifiers

PMID37151737

DOI10.1177/2050313X231169841

PMCPMC10154994

OpenAlexW4367459754

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.